ANeuroTech team,
decades of exerience in clinical drug evelopment

About us

Our Team is committed to the invention of new medicines to treat people suffering from depression and to the creation of substantial value for investors and partners.

We have comprehensive experience in the science and business of CNS drug discovery and development up till Market Authorization Approval.


Founding CEO and Chief Scientific Officer

Erik Buntinx, MD-Psychiatrist, Inventor

Experienced Chief Executive Officer with a demonstrated history of working in the pharmaceuticals industry Inventor of multiple worldwide granted patents in the field of neurosciences Veteran Principal Investigator in key drug development programs Senior Clinical Advisor on major CNS drug development programs

Partner and Executive Chairman

Rudi Pauwels, Baron Dr.

Dr. Rudi Pauwels is a pharmaceutical scientist with a specialization in virology and micro & nanotechnology and a serial biotech entrepreneur with a 35-year successful career in both academia and the biotech/pharmaceutical industry.

Partner & Strategic Business Development Advisor

Patrick Verheyen

Patrick Verheyen is the recently retired Global Head, Janssen Business Development for the Janssen Pharmaceutical Companies of Johnson & Johnson.

Strategic Advisor Global Regulatory Affairs

Karin Van Baelen

Karin Van Baelen is currently consultant in regulatory affairs and is the former Head Global Regulatory Affairs of Janssen, Pharmaceutical Companies of Johnson & Johnson.


Lars Bastiaanse

Former Compound Development Team Leader at J&J

Head CMC

Lieven Baert
PharmD, PhD, MBA

Previous Senior research fellow / Vice President early development and innovation, Johnson & Johnson


Didier de Chaffoy de Courcelles, PhD

Former Senior Vice-President Discovery and Early Development, Janssen

Head Non Clinical

Arthur Noach
PhD, PharmD

Non-Clinical Expert / Senior Consultant at Venn LS

Scientific Advisory Board

Prof. Charles B. Nemeroff, Chair

University of Texas

Prof. Dr. Alan Schatzberg

Stanford University

Prof. Philip Harvey

University of Miami

Dr. Tom Laughren

Former Head Psychiatric Products FDA

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry


Read more

Scroll to Top